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Mucosal and systemic vaccinationa b s t r a c t
This study demonstrates that route and viral vector can significantly influence the innate lymphoid cells
(ILC) and dendritic cells (DC) recruited to the vaccination site, 24 h post delivery. Intranasal (i.n.) vacci-
nation induced ST2/IL-33R+ ILC2, whilst intramuscular (i.m.) induced IL-25R+ and TSLPR+ (Thymic stromal
lymphopoietin protein receptor) ILC2 subsets. However, in muscle a novel ILC subset devoid of the known
ILC2 markers (IL-25R IL-33R TSLPR) were found to express IL-13, unlike in lung. Different viral vectors
also influenced the ILC-derived cytokines and the DC profiles at the respective vaccination sites. Both i.n.
and i.m. recombinant fowlpox virus (rFPV) priming, which has been associated with induction of high
avidity T cells and effective antibody differentiation exhibited low ILC2-derived IL-13, high NKp46+
ILC1/ILC3 derived IFN-c and low IL-17A, together with enhanced CD11b+ CD103 conventional DCs
(cDC). In contrast, recombinant Modified Vaccinia Ankara (rMVA) and Influenza A vector priming, which
has been linked to low avidity T cells, induced opposing ILC derived-cytokine profiles and enhanced
cross-presenting DCs. These observations suggested that the former ILC/DC profiles could be a predictor
of a balanced cellular and humoral immune outcome. In addition, following i.n. delivery Rhinovirus (RV)
and Adenovius type 5 (Ad5) vectors that induced elevated ILC2-derived IL-13, NKp46+ ILC1/ILC3-derived-
IFN-c and no IL-17A, predominantly recruited CD11b B220+ plasmacytoid DCs (pDC). Knowing that pDC
are involved in antibody differentiation, we postulate that i.n. priming with these vectors may favour
induction of effective humoral immunity. Our data also revealed that vector-specific replication status
and/or presence or absence of immune evasive genes can significantly alter the ILC and DC activity.
Collectively, our findings suggest that understanding the route- and vector-specific ILC and DC profiles
at the vaccination site may help tailor/design more efficacious viral vector-based vaccines, according
to the pathogen of interest.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the last two decades, inactivated, live attenuated, replication-
competent or -defective viruses have been extensively tested as
viral vector-based vaccines. Interestingly, poxviruses such as Mod-
ified Vaccinia Ankara (MVA), New York strain of vaccinia virus
(NYVAC), which are attenuated versions of vaccinia virus (VV),
and Avipoxvirus; canarypox and fowlpox (FPV) viruses, used in
prime-boost modalities have yielded uniquely different immune
outcomes, dependent upon the route of delivery and/or the vaccinevector combination [1–4]. For example, heterologous rFPV/rVV
compared to rVV/rFPV vaccination has shown to induce highly
poly-functional/ high avidity T cells [3,5–7], moreover, rMVA used
as a booster, as opposed to a prime has shown to induce more
effective T cell immunity [8–10]. Similarly, both replication-
competent and -defective recombinant Adenovirus-based vaccines
have also shown to induce T cell responses associated with
immune protection in animal models [11–13]. Moreover, viruses
such as, Influenza A, Human RV, Cytomegalovirus, and Vesicular
stomatitis virus, have also been assessed as promising vaccine
delivery vehicles [10,14–16]. In a recent prime-boost vaccination
study, mucosal RV prime vaccination was shown to induce HIV-
specific T cell responses associated with protection in mice [17].
To improve vaccine-specific immunity, variants of viral vectors,
S. Roy et al. / Vaccine 37 (2019) 1266–1276 1267such as IL-1bR and/or IL18 binding protein (IL-18bp) deletion
mutants of MVA and Adenoviral vectors have also been recently
tested [18–20]. Despite the knowledge of different viral vector-
based vaccines conferring different adaptive immune outcomes,
the underlying innate immune mechanisms governing these pro-
cesses at the vaccination site still remains elusive, specifically the
role of innate lymphoid cells (ILCs) and dendritic cells (DCs).
ILCs, although derived from a common progenitor, are lineage
negative in nature and according to the transcription factors,
receptors and cytokines they express, are broadly classified into
three main categories (ILC1, ILC2 and ILC3) [21]. ILC2, due to their
ability to express IL-13, have been heavily studied under chronic
inflammation, allergic asthma and helminth infections [22]. During
intracellular pathogen infection, ILC1 have shown to express IFN-c
and tumour necrosis factor (TNF)-a [23], whilst during extracellu-
lar bacterial and fungal infections, ILC3 have been associated with
interleukin (IL)-17A and IL-22 expression [24,25]. Although ILCs
have three distinct phenotypes, studies have shown that they have
the ability to interconvert between the phenotypes, according to
the external stimuli, and thus thought to be highly plastic
[26,27]. It is postulated that ILCs can polarize the immune
response, according to the immune cell milieu or pathogen
encountered, towards Th1, Th2 or Th17 immunity. However, the
role of ILCs in viral vector-based vaccination is not well
characterised.
DCs sample antigens at various body surfaces; skin, gastroin-
testinal tract and lungs, and are among the first line of defence
against many pathogens. Based on the anatomical location and
the invading pathogen, distinct DC subsets carry out differential
functions [28]. For example; lung DCs have been extensively stud-
ied under respiratory infections. Lung conventional CD11b+
CD103 DCs (cDCs) and cross-presenting CD11b CD103+ DCs have
been associated with CD8 T cell priming [29,30]. Although conflict-
ing evidence suggest that cDCs are functionally more important in
mounting an effective antiviral response [31,32], there is growing
evidence to support the notion that the activity of a particular
DC subset is determined by the specific infection. For example:
control of acute influenza virus infection is associated with CD11b
CD103+ DCs cross presentation to CD8 T cells [33], whilst, CD11b
CD8+ DCs, which share a common developmental origin with
CD11b CD103+ DCs, have been associated with activation of cyto-
toxic CD8 T cells against non-respiratory pathogens such as West
Nile Virus [34]. In the context of respiratory syncytial virus (RSV)
infection, CD11b+ and CD103+ DC subsets have been involved in
antigen presentation to both CD4 and CD8 T cells [35]. In addition,
during Influenza A infection, CD11b+ DCs have also been associated
with humoral immunity [36]. Furthermore, plasmacytoid DCs
(pDCs) also have been associated with distinct functions during
viral infections [37,38].
It is now well established that the route of delivery, cytokine
milieu, viral vectors and the order in which they are administered
can yield vastly different adaptive immune outcomes [3,5,7,39,40].
We have previously shown that (i) IL-13, although detrimental for
high avidity/poly-functional CD8 T cell immunity, was necessary
for effective antibody differentiation [41–43]. (ii) Using rFPV adju-
vanted vaccines that transiently inhibited IL-13 activity at the vac-
cination site, we have recently established that ILC2 (not other
lineage+ cells) were the major source of IL-13 at the vaccination
site 24 h post vaccination [44]. (iii) Furthermore, using the same
vaccines we have also shown that elevated IL-13 in the milieu
recruited CD11b CD103+ cross-presenting DCs, associated with
low avidity CD8 T cells [42,45]. Therefore, in this study to further
understand which specific innate immune cell subsets play a pre-
dominant role in shaping the downstream adaptive immune out-
comes, replicating and non-replicating viral vectors were
delivered intranasally and intramuscularly and subsequent ILC-derived cytokine profiles and DCs subsets were assessed 24 h post
vaccination.2. Results
2.1. Different viral vector-based vaccines can induce uniquely different
ILC2-derived 13 profiles following intranasal and intramuscular
vaccination
BALB/c mice were vaccinated intranasally or intramuscularly
with four different poxviral vectors rFPV, rMVA, rVV and
rMVADIL-1bR and three non-poxviral vectors Influenza A, Human
rhinovirus (RV) and Adenovirus type 5 (Ad5). Percentage of lung
and muscle ILC2 and their corresponding IL-13 expression were
assessed 24 h post vaccination. ILC2 were gated as CD45+ FSClow,
SSClow, lineage ST2/IL-33R+ cells for lung (Fig. S1) or lineage IL-
25R+, TSLPR+ and ST2/IL-33R+ for muscle (Fig. S2), as indicated in
Materials and Methods and Li et al 2018 [44]. Among all the vec-
tors tested, following i.n. delivery, Influenza A vector recruited
the highest percentage of Lin ST2/IL-33R+ ILC2 to the vaccination
site (lung mucosae). In contrast, RV and Ad5 recruited the lowest
percentage of ILC2, which was much lower than unimmunized
control (p = 0.0014 and p = 0.0011 respectively) (Fig. 1A and S3).
However, despite this, RV and Ad5 expressed elevated IL-13 levels,
which were similar to rMVA and Influenza A (Fig. 1B). Among the
three poxviral vectors tested, the highest IL-13 level was detected
in rMVA (rFPV vs rMVA p < 0.0001, rMVADIL-1bR vs rMVA
p < 0.0001), whilst rMVADIL-1bR showed the lowest (rFPV vs
rMVADIL-1bR p = 0.4159) (Fig. 1B). It is also noteworthy that, all
the vectors showed significantly elevated IL-13 expression by Lin
ST2/IL-33R+ ILC2 compared to the unimmunized control (rFPV
p = 0.0028; rMVA p < 0.0001; rMVADIL-1bR p = 0.0412; Influenza
A p < 0.0001; RV p < 0.0001; Ad5 p < 0.0001) (Fig. 1A and B).
Following i.m. vaccination, mainly IL-25R+ ILC2s and TSLPR+
ILC2, ranging from 0.25% to 2% were detected. In the context of
IL-25R+ ILC2, rMVA and Ad5 vector vaccination showed signifi-
cantly elevated numbers compared to unimmunised control
(p = 0.0183 and p = 0.0178 respectively). Furthermore, Ad5 vacci-
nation also showed higher proportion of IL-25R+ ILC2s compared
to influenza A (p = 0.0004) (Fig. 1G, H and I). Interestingly,
rMVADIL-1bR (1.8% average) showed a significantly elevated pro-
portion of TSLPR+ ILC2 compared to rFPV and rMVA vaccination
(p < 0.0001 and p = 0.0240 respectively) (Fig. 1G, H and I). Ad5 also
showed elevated TSLPR+ ILC2s compared to rFPV and influenza A
vaccination (p = 0.0103 and p = 0.0006 respectively) (Fig. 1G, H
and I). Following i.m. vaccination, similar to our previous studies
extremely low or no ST2/IL-33R+ ILC2 were detected with all vac-
cine groups tested (Fig. 1G, H and I).
Surprisingly, following i.m. delivery, canonical ILC2 subsets (IL-
25R+, TSLPR+) were found to express marginal IL-13. In contrast,
compared to the unimmunised control, a not yet defined ILC2 sub-
set that lacked IL-25R, ST2/IL-33R and TSLPR were found to express
IL-13 (Fig. 1E and F). Out of the vectors tested, Ad5 showed
remarkably higher proportion (2 to 3-fold) of IL-25R IL-33R
TSLPR cells expressing IL-13 (p < 0.0001) (Fig. 1E and F), which
was comparatively lower than i.n. Ad5 vaccination (Fig. 1B). It is
noteworthy that, the ILC2-derived IL-13 expression by each vector
was significantly higher following i.m. delivery compared to i.n.
delivery. (Note that: The parent ILC2 population in the i.m. groups
were much greater than the i.n. ST2+/IL-33R+ ILC2s. Thus, the differ-
ence in IL-13 expression by these two ILC subsets were also repre-
sented normalised to the CD45+ subset, described in materials and
methods (Fig. 1J).
Fig. 1. Evaluation of lung and muscle ILC2 and corresponding IL-13 expression following intranasal and intramuscular viral vaccination. BALB/c mice (n = 5–9 per group) were
i.n. or i.m. immunised with rFPV, rMVA, rMVA-DIL-1bR, Influenza A, RV or Ad5. 24 h post vaccination lungs were harvested and single cell suspensions were stained for ILC2s
and their IL-13 expression and analysed using flow cytometry. Cells were pre-gated on CD45+ FSClow SSClow cells using FlowJo software as described in Materials and Methods
and Figs. S1 and S2. Lung ILC2 graphs show (A) the percentage of Lin ST2/IL-33R+ ILC2 and (B) IL-13 expression by Lin ST2/IL-33R+ ILC2. (C) Representative FACS plots show
percentage of Lin ST2/IL-33R+ ILC2 expressing IL-13. Muscle ILC2 graphs show percentage of (D) Lin IL-25R TSLPR ST2/IL-33R ILC2 and (E) IL-13 expression by this novel
ILC2 subset. (F) Representative FACS plots show percentage of Lin IL-25R TSLPR– ST2/IL-33R ILC2 expressing IL-13, and graphs show muscle (G) IL-25R+ ILC2s, (H) TSLPR+
ILC2s and (I) ST2+/IL-33R+ ILC2s. To compare and contrast lung and muscle ILC2-derived IL-13, (J) bar graph represents IL-13 expression by Lin ST2/IL-33R+ ILC2 (i.n.) and
Lin IL-25 TSLPR ST2/IL-33R ILC2 (i.m.) following rFPV vaccination. Error bars represent Standard Error of mean (SEM) and p values were calculated using One-way
ANOVA followed by Tukey’s multiple comparison test (black lines) and paired student’s t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Experiments with
each vector were repeated minimum 2–3 times.
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ILC1/ILC3- derived IFN-c and IL-17A expression profiles
Our recent intranasal rFPV vaccination studies have shown that
the transient inhibition of ILC2-derived IL-13 at the vaccination
site can directly impact the level of IFN-c and IL-17A expression
by NKp46+ and NKp46 ILC1/ILC3s at the vaccination site 24 h post
vaccination [44]. Hence, we next investigated the induction of IFN-
c and IL-17A expression by ILC1/ILC3s by different viral vaccine
vectors as per indicated in Materials and Methods using flow
cytometry gating strategies described in Fig. S1. Following i.n. vac-
cination, although no significant differences in the percentages of
NKp46+ ILC1/ILC3s were detected compared to the unimmunized
control (Fig. 2A), compared to Influenza A, Ad5 showed signifi-
cantly reduced numbers of NKp46+ ILC1/ILC3s (p = 0.042). Whist
rMVADIL-1bR recruited NKp46+ ILC1/ILC3s similar to rFPV, rMVA
recruited significantly lower numbers of NKp46+ ILC1/ILC3s com-
pared to rFPV (p = 0.036). In the context of IFN-c expression by
NKp46+ ILC1/ILC3s, RV induced the highest (average 14.5%), fol-
lowed by Ad5 (average 5%) and rFPV (average 2.9%) (Fig. 2B).Unlike rFPV, the deletion mutant rMVADIL-1bR and rMVA showed
significantly lower IFN-c expression (p = 0.0187, and 0.0011
respectively), which was also lower than the unimmunized control
(p = 0.0086 respectively) (Fig. 2B). Expression of IFN-c by Influenza
A was similar to that of the unimmunized control.
Interestingly, following i.n. delivery 95–98% ILC1/ILC3s were
found to be NKp46 (Fig. 2A and D). Although there were no differ-
ences observed between the numbers of NKp46 ILC1/ILC3s
recruited by any of poxvirus vectors (Fig. 2D), IFN-c expression
was vastly different. rFPV was amongst the highest inducers of
IFN-c expression by NKp46 ILCs (Fig. 2E), whilst showing modest
IFN-c expression also by NKp46+ ILCs (Fig. 2B). Out of all the vac-
cine vectors tested, rMVADIL-1bR showed the lowest IFN-c expres-
sion by NKp46 ILC1/ILC3s (Fig. 2E). Although Influenza A
recruited significantly lower numbers of NKp46 ILC1/ILC3s com-
pared to RV and Ad5 (p = 0.0004, p < 0.0001 respectively), it
induced the highest IFN-c expression among the non-poxviral vec-
tors (Fig. 2E). Interestingly, the IFN-c expression by NKp46 ILC1/
ILC3s was very similar between Influenza A and rFPV vaccinated
groups (Fig. 2E). It is noteworthy that, although the unimmunized
Fig. 2. Evaluation of lung Lin ST2 NKp46+ and NKp46 ILC-derived IFN-c and IL-17A expression following intranasal viral vector vaccination. BALB/c mice (n = 5) were i.n.
immunised with same vectors as per in Fig. 1, and stained for Lin ST2/IL-33R NKp46+ and NKp46 ILC and their cytokine expression. Cells were pre-gated on CD45+ FSClow
SSClow cells as described in Materials and Methods and Fig. S1. Graphs show percentage of (A) Lin ST2/IL-33R NKp46+ ILC and (B) corresponding IFN-c and (C) IL-17A
expression by these cells, (D) percentages of Lin ST2/IL-33RNKp46 ILC and (E) corresponding IFN-c and (F) IL-17A expression. Error bars represent SEM and p values were
calculated using One-way ANOVA followed by Tukey’s multiple comparison test (black lines) and paired student’s t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. Representative FACS plots show IFN-c expression by Lin ST2/IL-33R NKp46+ (top) and NKp46 (bottom) ILC. Experiments for each group was repeated
minimum 2–3 times.
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expression of IFN-c was observed (Fig. 2D, E and S3). Remarkably,
rMVADIL-1bR induced the highest IL-17A expression by both
NKp46+ (Fig. 2C) and NKp46 ILC1/ILC3 subsets (Fig. 2F). rMVA
and Influenza A vectors induced modest IL-17A expression by both
these subsets, whilst rFPV, Ad5 and RV showed no IL-17A expres-
sion, similar to the unimmunized control (Fig. 2C and F).
Unlike i.n., following i.m. delivery, the proportion of NKp46+
ILC1/ILC3 in the muscle was very minimal (0–0.8%) across all vac-
cine vectors (Fig. 2A and Fig. 3A), with significant differences
observed between rMVA compared to rFPV, rMVADIL-1bR and
Ad5 (p = 0.0087p = 0.0049, and p = 0.0397 respectively). Addition-
ally, only rFPV and Influenza A vaccinated groups showed any
expression of IFN-c by NKp46+ ILC1/ILC3 (Fig. 3B). Interestingly,
IFN-c expression by these subsets was much greater following i.
m versus i.n. vaccination (rFPV i.m. 12.06% i.n. 2.5% and influenza
A i.m.  4.67% i.n. 1.5%) (Fig. 2B and Fig. 3B). In the context of IL-
17A expression by NKp46+ ILC1/ILC3, only Influenza A vaccinated
animals showed any significant expression (average 8.39%,
p < 0.0001 influenza A vs. all vaccine vectors) (Fig. 3C). Of the
poxviral vectors tested, rMVADIL-1bR vaccinated group also
showed an increase in the proportion of NKp46+ ILC1/ILC3 express-
ing IL-17A (average 0.89%) although not significant and was similar
to what was observed with i.n. delivery (average 1.0%).
Moreover, following i.m. delivery, different IFN-c and IL-17A
expression profiles were detected by NKp46 ILC1/ILC3. Unlike i.
n. delivery, very low IFN-c expression was detected following i.
m. vaccination, and only influenza A (0.01%) and Ad5 (0.03%)
showed any IFN-c expression (Fig. 2E and Fig. 3E). All vectors
showed different NKp46 ILC1/ILC3-derived IL-17A expressionprofiles. Specifically, out of the vectors tested, Ad5 and rMVADIL-
1bR showed the highest expression (0.58% and 0.84% respec-
tively) (Fig. 3F). Interestingly, the NKp46 ILC1/ILC3-derived IL-
17A expression by the rMVADIL-1bR group was significantly ele-
vated compared to unimmunised, rFPV, rMVA and influenza A
(p < 0.0001, p = 0.0064, p < 0.0001, and p < 0.0001 respectively)
(Fig. S4). Whilst, Ad5 showed significant differences compared to
unimmunised, rMVA, and influenza A vaccinated groups
(p = 0.0048, p = 0.0172 and p = 0.0219 respectively) (Fig. S4).
2.3. rFPV and rMVADIL-1bR lead to preferential recruitment of CD11b+
CD103 conventional DCs to the lung mucosae, 24 h post intranasal
vaccination
Our previous studies have shown that transient inhibition of IL-
13 at the vaccination site can significantly modulate DC recruit-
ment and resulting avidity of CD8+ T cells, including B cell immu-
nity [41,42,45]. Since we have shown that ILC2 are the major
source of IL-13 at the vaccination site and this is also viral
vector-dependent [44], in this study we have also assessed the
influence of viral vector on lung DC recruitment 24 h post i.n. vac-
cination (as per indicated in Figs. S5). In this study, four different
lung DC subsets was assessed (CD11b+ CD103 cDC, CD11b
CD103+ cross-presenting DC, CD11b CD8+ cross-presenting DC
and CD11b B220+ pDC (not other immune cell infiltrates)). Per-
centage of each DC subset, for a given viral vector was calculated
as a proportion of total MHC-II+ CD11c+ DCs, as described in Mate-
rials and Methods.
In agreement with Trivedi et al 2014, these studies also showed
that rFPV recruited significantly elevated proportions of CD11b+
Fig. 3. Evaluation of muscle Lin ST2 NKp46+ and NKp46 ILC-derived IFN-c and IL-17A profiles post intramuscular viral vector vaccination. BALB/c mice (n = 5–9) were i.m.
immunised with rFPV, rMVA, rMVA-DIL-1bR, Influenza A or Ad5. 24 h post vaccination muscles were harvested and cell suspensions were stained for Lin ST2/IL-33R
NKp46+ and NKp46 ILC and their cytokine expression. Cells were pre-gated on CD45+ FSClow SSClow cells as described in Materials and Methods and Fig. S2. (A) Graphs show
percentage of Lin ST2/IL-33R NKp46+ ILCs and (B) corresponding IFN-c and (C) IL-17A expression by theses cells, (D) percentage of Lin ST2 NKp46 ILCs and (E) their
corresponding IFN-c and (F) IL-17A expression. Error bars represent SEM and p values were calculated using One-way ANOVA followed by Tukey’s multiple comparison test
(black lines) and paired student’s t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Representative FACS plots show IFN-c and IL-17A expression by Lin ST2/
IL-33R NKp46+ (top) and NKp46 (bottom) ILC. Experiments for each group was repeated minimum 2–3 times.
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respectively). Additionally, the deletion mutant rMVADIL-1bR
recruited the highest percentage of CD11b+ CD103 cDCs, whilst
Ad5 recruited the lowest (Fig. 4A and B). Furthermore, CD11b+
CD103 cDC recruitment by Influenza A was similar to that of rFPV,
rMVA, rVV and RV (Fig. 4A and B). Compared to the unimmunized
control, rFPV, rMVADIL-1bR and Influenza A showed significant
elevated CD11b+ CD103 cDC recruitment (p = 0.0069, p < 0.0001
and p = 0.0077 respectively).2.4. Intranasal rVV vaccination recruited elevated numbers of CD11b
CD103+ and CD11b CD8+ cross-presenting DCs to the lung mucosae
24 h post vaccination
Unlike CD11b+ CD103 cDC recruitment, rFPV induced signifi-
cantly lower CD11b CD103+ cross-presenting DCs compared to
that of the unimmunized control (p = 0.0224), and these values
were significantly lower than that of rVV, Influenza A and RV vec-
tors (p < 0.0001, p = 0.0065 and p < 0.0001 respectively) (Fig. 4A
and C). Interestingly, compared to all viral vectors tested, rVV
recruited the highest percentage of CD11b CD103+ cross-
presenting DCs to the lung mucosae 24 h post vaccination. Whilst,
rFPV recruited the lowest number similar to rMVA, rMVADIL-1bR
and Ad5 (Fig. 4C). Furthermore, the proportion of CD11b CD8+
cross-presenting DCs recruited by all the vaccine vectors showed
a comparable profile to that of the CD11b CD103+ cross-
presenting DCs, where rVV showed the highest proportion of
CD11b CD8+ cross-presenting DCs (Fig. 5A and C). It is notewor-
thy that the cross-presenting CD11b CD103+ DCs recruited by
rVV, Influenza A and RV were significantly higher than unimmu-nized control (p < 0.0001, p = 0.0067 and p = 0.0113 respectively)
(Fig. 4A and C). Whereas, cross-presenting CD11b CD8+ DCs
recruited by rVV and Influenza A although were significantly
higher than unimmunized control (p < 0.0001, p = 0.0498 respec-
tively), Ad5 recruitment was significantly lower (p = 0.0164)
(Fig. 5A and C).
2.5. Compared to the other viral vectors, RV and Ad5 recruited elevated
CD11b B220+ plasmacytoid DCs to the lung mucosae 24 h post
intranasal vaccination
Next when the CD11b B220+ pDC recruitment profile was
assessed, these DCs showed a unique profile compared to the other
three DC subsets examined. At 24 h post vaccination, RV and Ad5
recruited the highest percentage of CD11b B220+ pDCs to the lung
mucosae, whilst Influenza A, rFPV and rMVADIL-1bR showed the
lowest (Fig. 5B and D). Among the poxviral vectors, rVV recruited
the highest proportion of CD11b B220+ pDCs whilst rFPV
recruited the lowest, and rMVA and rMVADIL-1bR showed a simi-
lar pDC profile. Compared to the unimmunised control, rVV, RV
and Ad5 vectors showed significant differences in pDC recruitment
24 h post vaccination (p = 0.0025, p < 0.0001 and p < 0.0001 respec-
tively) (Fig. 5B and D).
2.6. Following intranasal vaccination different viral vectors showed
different kinetic profiles 0 to 48 h post vaccination
Next, we also evaluated the DC recruitment kinetics 0 to 48 h
post vaccination. Distinct DC kinetic profiles for each of the vectors
were detected over time. rFPV showed significant regulation of
Fig. 4. Evaluation of CD11b+ CD103 cDCs and CD11b CD103+ cross-presenting DCs following intranasal viral vector vaccination. BALB/c mice (n = 5) were i.n. immunised
with rFPV, rMVA, rMVA-DIL-1bR, rVV, Influenza A, RV or Ad5. 24 h post vaccination lungs were harvested single cell suspensions were prepared and stained for different DC
subsets and analysed using flow cytometry as described in Materials and Methods. Cells were pre-gated on MHC-II+ CD11c+ cells using fluorescence minus one (FMO) controls
for each virus as described in Materials and Methods and Fig. S5. (A) Representative FACS plots show percentage of CD11b+ CD103 DCs (gated top left) and CD11b+ CD103
DCs (gated bottom right) recruited to lung mucosae. (B) Percentage of CD11b+ CD103 DCs and (C) CD11b CD103+ DCs are shown as bar graphs, recruited by each vaccine
vector. Percentages were calculated as a proportion of total MHC-II+CD11c+ DCs generated by each vector as indicated in Materials and Methods. Error bars represent SEM and
p values were calculated using One-way ANOVA followed by Tukey’s multiple comparison test (black lines) and paired student’s t test (grey lines). *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. Experiments with each vector were repeated minimum 2–3 times.
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by the rMVA deletion variant (rMVADIL-1bR), unlike the parental
rMVA (Fig. 6A and S6). The replication competent rVV showed reg-
ulation of all DC subsets, with significant modulation of cross-
presenting DCs. Interestingly, cDC recruitment kinetics between
rVV, rMVA and Influenza were very similar (Fig. 6B and S6). Ad5
recruited a pDC profile similar to RV and a CD11b CD8+ profile
similar to rVV (Fig. 6B, C and S6).3. Discussion
This study has clearly demonstrated that not only the route of
vaccination, but also different viral vector-based vaccines can
induce significantly different ILC subsets at the respective vaccina-
tion sites 24 h post delivery. In the context of ILC2, Lin ST2/IL-
33R+ ILC2 were predominant in lung, whilst Lin IL-25R+ or/and
Lin TSLPR+ ILC2 were found in muscle 24 h post viral vector vac-
cination. This was not entirely surprising as Lin IL-25R+ ILC2 has
been associated with circulation [46,47], whilst Lin TSLPR+ ILC2
is known to be skin-resident [48]. Although, Lin ST2/IL-33R+
ILC2 was the major source of IL-13 in lung, Lin IL-25R TSLPR
ST2/IL-33R ILC2s were the predominant source of IL-13 in muscle.
Interestingly, recently we have also found that following viral vec-
tor vaccination IL-5 expression was specific to lung ILC2, not mus-
cle (Jaeson et al. submitted), reaffirming that ILCs can be highly
plastic under different conditions (specifically chronic inflamma-
tory conditions versus vaccination or infection) [26,49], and why
different routes of delivery may yield uniquely different innate
and adaptive immune outcomes.
In addition to ILC2, i.n. versus i.m. vaccinations induced differ-
ent proportions of NKp46+ ILC1/ILC3s unlike NKp46 ILC1/ILC3s.
Specifically, significantly lower numbers of NKp46+ ILC1/ILC3s
were detected in muscle compared to the lung (1% vs 4–8%), con-
firming that circulatory ILC1/ILC3s are scarce as opposed to tissueresident ILCs [50]. Both NKp46+ and NKp46 ILC1/ILC3s were able
to express different levels of IFN-c, that were vaccine route- and
vector-dependent. Specifically, whilst both NKp46+/ ILC1/ILC3
subsets were able to express IFN-c in lung, only the NKp46+ ILCs
in muscle expressed IFN-c, albeit by two vaccination groups,
where the expression was in the order of rFPV > Influenza A. More-
over, muscle NKp46cells expressed extremely low IFN-c follow-
ing Influenza and Ad5 vaccination. Majority of i.m. delivered
vectors induced elevated ILC2-driven IL-13 and minimal ILC1/
ILC3-driven IFN-c expression compared to i.n. delivery. Addition-
ally, our previous studies with pox-viral vectors have shown that,
compared to i.m., i.n. delivery can induce T cells of higher avidity,
associated with low IL-13 at the vaccination site [5,6,44]. Further-
more, i.n. rFPV priming has shown to induce high avidity T cells
compared to i.n. rVV and Influenza priming vaccination [3,7,51],
(Tan, Derose et al. personal communication). In agreement with
our current study, i.n. Ad5 vaccination has also shown comparable
ILC2 gene expression profiles to i.n. rFPV, unlike i.m. Ad5 delivery
(Jaeson et al. submitted). Taken together, these findings may
explain why systemic vaccination with some viral vectors may lead
to suboptimal antiviral immunity, compared to mucosal vaccina-
tion [6,7,52,53].
Besides the route of delivery, each viral vector also induced a
uniquely different ILC2-driven IL-13 and ILC1/ILC3-driven IFN-c
expression profiles. Specifically, both i.n. and i.m. rFPV vaccination
induced low ILC2-derived IL-13, and high NKp46+ or NKp46 ILC1/
ILC3-derived IFN-c. In contrast, i.m. rMVA vaccination induced
lower ILC2-derived IL-13 compared to i.n. delivery. Knowing that,
low IL-13 is associated with improved T cell immunity, our current
data may explain why previously rMVA has been found to be more
efficacious as an i.m. delivery vector than a mucosal delivery vector
[8,10]. Moreover, whilst i.n. delivery of rMVA, Influenza A, RV and
Ad5 induced elevated ILC2-derived IL-13, the expression of IFN-c
was lower in NKp46+ ILC1/ILC3s following rMVA, Influenza A;
Fig. 5. Evaluation of CD11b CD8+ cross-presenting and CD11b B220+ pDC subsets following intranasal viral vector vaccination. BALB/c mice (n = 5) were i.n. immunised
with same vectors as in Fig. 4 and lung cells were analysed using flow cytometry for DC subsets as per described in Materials and Methods. Cells were pre-gated on MHC-II+
CD11c+ cells using fluorescence minus one (FMO) controls as described in Fig. S5. Left panel bar graphs show (A) percentage of CD11b CD8+ DCs and (B) CD11b B220+ DCs
recruited to the lung mucosae compared to the unimmunised control. Right panel representative FACS plots show percentage of (C) CD11b CD8+ DCs and (D) CD11b B220+
DCs recruited to the vaccination site 24 h post vaccination by each vector. Percentages were calculated as a proportion of total MHC-II+CD11c+ DCs generated by each vector
as indicated in Materials and Methods. Error bars represent SEM and p values were calculated using One-way ANOVA followed by Tukey’s multiple comparison test (black
lines) and paired student’s t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Experiments with each vector were repeated minimum 2–3 times.
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estingly, we have previously shown that IL-4R antagonist adju-
vanted vaccination that transiently inhibited IL-13 signalling via
STAT6, induced low ILC2-derived IL-13 expression associated with
elevated expression of NKp46 ILC1/ILC3-derived IFN-c [44]. Addi-
tionally, enhanced IfngR gene expression on ILC2 was also recently
associated with low ILC2-derived IL-13 (Jaeson et al. submitted).
Taken together, these observations suggest that enhanced ILC1/
ILC3-derived IFN-c expression regulates ILC2-derived IL-13 at the
vaccination site, similar to the Th1/Th2 paradigm. Hence, we pro-
pose that ILC-derived IL-13 and IFN-c balance at the vaccination
site crucially impacts the downstream vaccine-specific immunity.
Different vectors also lead to differential expression of IL-17A
by NKp46+ and NKp46 ILC1/ILC3. Specifically, i.n. rMVA,
rMVADIL-1bR and Influenza A vectors induced elevated IL-17A
by both ILC1/ILC3 subsets at the lung mucosae 24 h post vaccina-
tion. However, majority of the vectors induced different levels of
IL-17A by NKp46 ILC1/ILC3 subsets in the muscle. In asthma stud-
ies the importance of maintaining IL-13 and IL-17 balance has been
well documented [54]. Similarly, our vaccination studies have also
shown that IL-13 can regulate IL-17A expression on T cells at the
transcriptional and translational level, and IL-17A is associated
with T cell mediated protective immunity [55]. Knowing that (i)
rVV and its derivatives (rMVA) perform better as a booster vaccine
than a prime [7,8] (ii) Influenza A prime yield poor adaptiveimmune outcomes (Tan, Derose et al. personal communication)
[51] and (iii) systemic Ad5 immunization have shown to induce
less effective antiviral T cell responses [12,56–58], collectively
our data suggest that the early onset of high ILC1/ILC3-derived
IL-17A together with low IFN-c and high ILC2-derived IL-13 could
be detrimental for inducing effective cellular immunity.
Our study demonstrated that in addition to different ILC pro-
files, mucosal vaccination with different viral vectors yielded
uniquely different lung DC profiles at the vaccination site 24 h post
vaccination. We have previously shown that IL-13 levels at the vac-
cination site can significantly alter DC phenotype, specifically, inhi-
bition of IL-13 can recruit elevated CD11b+ CD103 cDCs
associated with high avidity T cells [45]. This study further sub-
stantiated our previous findings of enhanced recruitment of
CD11b+ CD103 cDCs as opposed to CD11b CD103+ cross-
presenting DCs following i.n. rFPV vaccination. Moreover, moder-
ate proportions of CD11b B220+ pDCs were also observed with
rFPV vaccination. pDCs are known to induce antibody differentia-
tion via IFN-c production [40] and their clustering with cDCs have
shown to induce efficient T cell mediated antiviral immunity [38].
We have already established that rFPV priming can induce robust
high avidity T cells and differentiated antibodies, involved in pro-
tective immunity against viral pathogens such as HIV [7,41]. Thus,
our current findings suggest that although in the context of certain
viral vectors, the cDC/pDC balance may govern the quality of T and
Fig. 6. DC kinetics following intranasal viral vector based vaccination 0–48 h post vaccination. BALB/c mice (n = 5) were i.n. immunised with rFPV, rVV and Ad5. Lungs were
harvested at 12, 24 and 48 h post vaccination and lung DC subsets and analysed using flow cytometry as described in Materials and Methods. Cells were pre-dated on MHC-II+
CD11c+ cells using fluorescence minus one (FMO) controls as described in Fig. S5. Line graphs (left panel) and bar graphs (right four panels) show percentage of CD11b+
CD103 DCs (red), CD11b CD103+ DCs (green), CD11b CD8+ DCs (black) and CD11b B220+ DCs (blue) recruited by (A) rFPV, (B) rVV and (C) Ad5 to the lung mucosae 0 to
48 h post vaccination. Error bars represent SEM and p values were calculated using One-way ANOVA followed by Tukey’s multiple comparison test (black lines) and paired
student’s t test (grey lines). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Experiments with each vector were repeated minimum 2–3 times. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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employ other mechanisms (as Influenza A showed similar cDC/
pDC profile to rFPV associated with poor quality T cells).
In contrast to rFPV vaccination, rMVA lead to elevated ILC2-
derived IL-13, similar to rVV (data not shown), and both vectors
significantly enhanced recruitment of CD11b CD103+ cross-
presenting DCs to the lung mucosae, as shown previously [45]. This
may explain why rMVA and rVV priming lead to low avidity T cells
following recombinant HIV vaccination [3,7]. Moreover, intranasal
Influenza A, RV and Ad5 vaccination which also lead to high ILC2-
derived IL-13, preferentially induced CD11b CD103+ cross-
presenting DCs as opposed to cDCs. In a prime-boost vaccine
modality, recombinant Influenza A priming has shown to induce
enhanced magnitude of vaccine-specific T cells, however, are of
low avidity unlike rFPV priming (Tan, Derose et al. personal com-
munication). Similarly, recombinant Ad5 vaccination has also
shown to induce high magnitude of vaccine-specific CD8 T cells
[13]. Therefore, these observations suggest that these vectors
although lead to enhanced magnitude of vaccine-specific T cell
immunity (IFN-c production by T cells), may lead to low avidity
T cells against chronic infections such as HIV-1. Despite low cDCs,
Ad5 and RV exhibited a bias towards pDC recruitment. Knowing
that pDC-driven IFN-c can induce effective antibody responses,
we postulate that Ad5- and RV-based vaccines could be more effi-
cacious in inducing humoral immunity. Similar to CD11b CD103+
cross-presenting DCs, rVV additionally induced elevated CD11b
CD8+ cross-presenting DCs to the lung mucosa. These observations
suggested that, early induction of CD11b CD8+ cross-presenting
DCs, could also be associated with induction of low avidity T cells.However, in the context of some pathogens, (for example, Leishma-
nia, and also some viruses, Infleunza and HSV-1 infections), induc-
tion of cross-presenting DCs have been associated with protective
immunity [30,59,60]. Thus, when designing recombinant viral
vector-based vaccines, careful selection of the vector, according
to the pathogen of interest may be of great importance.
rMVADIL-1bR is known to induce effective memory T cell
responses compared to parental rMVA vaccination [61]. Unlike
rMVA, rMVADIL-1bR induced low ILC2-derived IL-13 and elevated
cDCs similar to rFPV, which has shown to induce high avidity T
cells with better protective immunity. These findings indicated
that removal of a single immune evasive gene from the viral vector
can significantly alter the innate immune outcomes, specifically
the ILCs and DCs, associated with effective protective immunity.
However, compared to rFPV (which showed elevated IFN-c and
no IL-17A expression), rMVADIL-1bR vaccination induced subopti-
mal ILC1/ILC3-derived IFN-c and high IL-17A expression at the vac-
cination site. It is well established that IFN-c is crucial for antiviral
immunity, and overexpression of IL-17A can lead to immune
imbalance [62]. It is also known that viral IL-18 bp neutralize host
IL-18 and prevent IFN-c production [63]. Thus, the residual IL-
18 bp in the rMVADIL-1bR vector could be responsible for the
observed ILC1/ILC3-derived IFN-c profile. Thus, we postulate that
rMVA vector lacking both IL-1bR and IL-18 bp genes may lead to
ILC/DC profiles similar to rFPV and balanced T and B cell outcomes.
Furthermore, rVV, rMVA and rMVADIL-1bR data clearly demon-
strated that the attenuation status of a viral vector and the pres-
ence or absence of virokines significantly modulated the ILC
cytokine expression and DC profile. The rFPV and rMVADIL-1bR
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immune system could be more efficacious at inducing vaccine-
specific immunity in humans (e.g.- Avipoxvirus compared to
Orthopoxvirus). These observations strongly highlight the notion
that when designing viral vector-based vaccines, in addition to
the safety and genetic stability, inherent properties of the viruses
themselves need serious consideration (in this case, its replicative
ability within the mammalian host).
We have previously shown that ILC2s are the only source of IL-
13 at the vaccination site, 24 h post vaccination and IL-13 level in
the milieu can crucially impact the DC recruitment at the lung
mucosae [42,44,45]. Hence, collectively our findings suggest that,
early ILC2-derived IL-13, together with ILC1/ILC3-derived IFN-c
and IL-17A, differentially impact DC recruitment/regulation at
the vaccination site, associated with adaptive immune outcomes
and this warrants further investigation. Therefore, we postulate
that (i) following vaccination, ILC and DC profiles may act as pre-
dictors of downstream vaccine-specific immunity and (ii) selection
of viral vector according to the pathogen of interest (eg: virus, bac-
teria or parasites) may help tailor/design effective viral-vector
based vaccines against chronic pathogens.4. Materials and Methods
Mice. Pathogen-free 6–8 weeks old female BALB/c mice were
purchased from the Australian Phenomics Facility, The Australian
National University. All animals were maintained, monitored daily
and cervically dislocated at the endpoint according to the Aus-
tralian NHMRC guidelines within the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes and in
accordance with guidelines approved by the ANU Animal Experi-
mentation and Ethics Committee (AEEC), protocol number
A2014/14 and A2017/15.
Viral vector-based Vaccines. Recombinant FPV, VV and MVA
expressing HIV antigens described previously were used in this
study [44,64]. The rMVADIL-1bR was constructed and kindly pro-
vided by Dr. Jackson. Influenza A and Adenovirus (Ad5) vectors
were kindly provided by Prof. Arno Mullbacher, JCSMR, ANU.
Recombinant Human Rhinovirus serotype 1A (RV) was kindly pro-
vided by Prof. Gowans and Dr. Wijesundara, Basil Hetzel Institute,
University of Adelaide [16].
Immunisation. BALB/c mice were intranasally or intramuscu-
larly immunised with 1x107 plaque forming units (pfu) of each
of the poxviruses rFPV, rVV, rMVA, rMVA-DIL-1bR; 2x107 pfu (i.
n.) or 2.5x107 pfu (i.m.) of Ad5, 5  106 TCID50 of RV or 500 pfu
of Influenza A. Note that, doses used were comparable to those
used in previous studies, optimal to induce adaptive immune out-
comes. Mice were vaccinated with 10 mL per nostril (i.n.) or
50 lL per leg (i.m.) under mild isofluorane anaesthetic. rFPV, rVV,
rMVA, rMVA-DIL-1bR were sonicated three times for 15 s on ice
at 50% capacity using Branson Sonifier 450 immediately prior to
vaccination.
Preparation of lung lymphocytes. Lung tissues were collected
24 h post vaccination in complete RPMI for ILC studies as described
previously [44]. For DC studies, lungs were harvested at 12, 24 and
48 h post vaccination. Lung tissues were prepared as described
previously [44]. Briefly, tissues were cut into small pieces, and
enzymatically digested for 45 min at 37 C in digestion buffer con-
taining 1 mg/ml collagenase (Sigma-Aldrich, St Louis, MO), 1.2 mg/
ml Dispase (Gibco, Auckland, NZ), 5 Units/ml DNase (Calbiochem,
La Jolla, CA) in complete RPMI. Samples were crushed and passed
through a 100 mm falcon cell strainer and resulting lung cell sus-
pensions were then treated with red cell lysis buffer followed by
extensive washing to remove the lysis buffer. Samples were then
passed through gauze to remove debris, cells were re-suspendedin complete RPMI, rested overnight at 37 C under 5% CO2 as per
our previous studies prior to staining [5,42].
Preparation of muscle lymphocytes. Muscle tissues were har-
vested 24 h post vaccination in complete RPMI and prepared as
previously indicated [44]. Briefly, tissues were, homogenised and
enzymatically digested for 45 min at 37 C in a digestion buffer
containing 2 mg/mL collagenase, 2.4 mg/mL dispase and 5 Units/
mL of DNAse in complete RPMI. Subsequently, samples were very
gently pushed through a 70 lM Falcon cell strainer, to avoid debris.
Resulting cell suspension was then washed, resuspended in com-
plete RPMI and rested overnight as per lung prior to staining [5,42]
Evaluation of lung and muscle ILCs using flow cytometry.
Monoclonal antibodies FITC-conjugated anti-mouse CD3 (T cells)
clone 17A2, CD19 (B cells) clone 6D5, CD11b (macrophages and
dendritic cells) clone M1/70, CD11c (dendritic cells) clone N418,
CD49b (NK, NKT, T cells) clone HMa2, FceRIa (Mast cells and Baso-
phils) clone MAR-1 (all linage positive markers were selected as
FITC), PE-conjugated anti-mouse ST2/IL-33R (clone DIH9), APC-
conjugated IL-25R (clone 9B10), APC/Cy7-conjugated anti-mouse
CD45 (clone 30-F11), Brilliant Violet 421-conjugated anti-mouse
CD335 (NKp46) (clone 29A1.4), Brilliant Violet 510-conjugated
anti-mouse IFN-c (clone XMG1.2), Alexa Fluor 700-conjugated IL-
17A (clone TC11-18H10.1) were obtained from BioLegend. PE-
eFluor 610-conjugated anti-mouse IL-13 (clone eBio13A) was pur-
chased from eBioscience and APC- conjugated anti-mouse TSLPR
R&D systems. ILC2 and ILC1/3s were stained separately to avoid
fluorochrome overlap. Specifically, FITC-conjugated lineage cock-
tail antibodies and APC/Cy7-conjugated anti-mouse CD45 were
used in both ILC2 and ILC1/ILC3 staining. For lung and muscle
ILC2 staining, PE-conjugated anti-mouse ST2/IL-33R, and PE-
eFluor 610-conjugated anti-mouse IL-13 were used and for muscle
ILC2 staining, additionally APC-conjugated IL-25R and APC-
conjugated anti-mouse TSLPR were used. Brilliant Violet 421-
conjugated anti-mouse NKp46, Brilliant Violet 510-conjugated
anti-mouse IFN-c, Alexa Fluor 700-conjugated IL-17A were only
used in ILC1/3s staining. Briefly, for intracellular staining, samples
were treated with Brefeldin A for 5 h, washed, cell surface staining
was performed followed by and intracellular staining after fixing
and permeabilising the cells as per our previous protocols[42].
Once the staining was completed all samples were fixed with
0.5% paraformaldehyde, 1.4  106 events from each lung sample
were acquired and 3.0  106 events were acquired for muscle on
a BD LSR Fortessa. Data were analysed using Tree Star FlowJo soft-
ware (version 10.0.7) using gating strategies indicated in Figs. S1
and S2.
Evaluation of lung DCs using Flow cytometry. 2  106 cells
were blocked with anti-mouse CD16/CD32 Fc Block antibody (BD
Biosciences, USA) for 20 min at 4 C and cells were surface stained
with APC conjugated MHCII I-Ad (e-Biosciences, USA), biotin con-
jugated CD11c (N418 clone, Biolegend, USA), followed by strepta-
vidin Brilliant violet 421 (Biolegend, USA) and other DC markers
CD8 APC-eFluor780 (53–6.7 clone, ebiosciences, USA), B220
PercpCy5.5 (RA3-6B2 clone, e-Biosciences, USA), CD11b AlexaFluor
700 (M1170 clone, Biolegend, USA) and CD103 FITC (2E7 clone, e-
Biosciences, USA) for 30 min on ice. Cells were resuspended in PBS
and analysed using BD LSRII flow cytometer Becton Dickinson, San
Diego, CA). 5  105 events per sample were collected and results
were analyzed using FlowJo software version 10.0.7, as described
in Fig. S2. Note that, live/dead staining was also performed using
viability dye 7-amino-actinomycin D (7-AAD Biolegend, USA)
(Figs. S2A and S2B).
Statistical analysis. Cytokine expression by ILCs was calculated
as a percentage of the parent ILC subset. To depict the differences
in IL-13 expression, following i.n. vs i.m. vaccinations, number of
ILC2 expressing IL-13 were also back calculated to CD45+ popula-
tion and normalized to 1  106. The muscle ILC2 subset percent-
S. Roy et al. / Vaccine 37 (2019) 1266–1276 1275ages were calculated as (subset of interest/Lin popula-
tion  100%). The DC subsets were represented as a percentage of
total MHC-II+ CD11c+ DCs. The p-values were calculated using
two-tailed paired parametric student’s t-test, unpaired parametric
student’s t-test or Ordinary One-way ANOVA with Tukey’s multiple
comparison post-test. All experiments were repeated minimum 2–
3 times.5. Data availability
The authors declare that all data supporting the findings of this
study are available within the paper and supplementary files.
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